Dan Wang

List of Publications by Year in Descending Order

37 papers	1,873 citations	21 h-index	43 g-index
52 ext. papers	2,620 ext. citations	12.4 avg, IF	5.66 L-index

#	Paper	IF	Citations
37	AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice.. *Nature*, **2022**,	50.4	3
36	Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo. *Nature Communications*, **2021**, 12, 6267	17.4	5
35	Single-cell sequencing reveals suppressive transcriptional programs regulated by MIS/AMH in neonatal ovaries. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	5
34	AAV-Mediated Gene Therapy for Glycosphingolipid Biosynthesis Deficiencies. *Trends in Molecular Medicine*, **2021**, 27, 520-523	11.5	0
33	Bone-Targeting AAV-Mediated Gene Silencing in Osteoclasts for Osteoporosis Therapy. *Molecular Therapy - Methods and Clinical Development*, **2020**, 17, 922-935	6.4	8
32	CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors. *Cell*, **2020**, 181, 136-150	56.2	137
31	AAV-Genome Population Sequencing of Vectors Packaging CRISPR Components Reveals Design-Influenced Heterogeneity. *Molecular Therapy - Methods and Clinical Development*, **2020**, 18, 639-651	6.4	12
30	Adeno-associated virus vector as a platform for gene therapy delivery. *Nature Reviews Drug Discovery*, **2019**, 18, 358-378	64.1	555
29	Viral Vectors for Muscle Gene Therapy **2019**, 179-192		
28	Bone-targeting AAV-mediated silencing of Schnurri-3 prevents bone loss in osteoporosis. *Nature Communications*, **2019**, 10, 2958	17.4	29
27	Gene Delivery to Nonhuman Primate Preimplantation Embryos Using Recombinant Adeno-Associated Virus. *Advanced Science*, **2019**, 6, 1900440	13.6	4
26	Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity. *JCI Insight*, **2019**, 5,	9.9	14
25	Single-cell sequencing of neonatal uterus reveals an Misr2+ endometrial progenitor indispensable for fertility. *ELife*, **2019**, 8,	8.9	18
24	Intrathecal Adeno-Associated Viral Vector-Mediated Gene Delivery for Adrenomyeloneuropathy. *Human Gene Therapy*, **2019**, 30, 544-555	4.8	12
23	Taking a Hint from Structural Biology: To Better Understand AAV Transport across the BBB. *Molecular Therapy*, **2018**, 26, 336-338	11.7	2
22	Streamlined ex vivo and in vivo genome editing in mouse embryos using recombinant adeno-associated viruses. *Nature Communications*, **2018**, 9, 412	17.4	41
21	A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates. *Molecular Therapy - Methods and Clinical Development*, **2018**, 9, 234-246	6.4	26

20	In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency. *Human Gene Therapy*, **2018**, 29, 853-860	4.8	40
19	Slow Infusion of Recombinant Adeno-Associated Viruses into the Mouse Cerebrospinal Fluid Space. *Human Gene Therapy Methods*, **2018**, 29, 75-85	4.9	3
18	Cas9-mediated allelic exchange repairs compound heterozygous recessive mutations in mice. *Nature Biotechnology*, **2018**, 36, 839-842	44.5	23
17	Adeno-Associated Virus Neutralizing Antibodies in Large Animals and Their Impact on Brain Intraparenchymal Gene Transfer. *Molecular Therapy - Methods and Clinical Development*, **2018**, 11, 65-72	6.4	27
16	AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E1688-E1697	11.5	98
15	Short DNA Hairpins Compromise Recombinant Adeno-Associated Virus Genome Homogeneity. *Molecular Therapy*, **2017**, 25, 1363-1374	11.7	36
14	Slow Intrathecal Injection of rAAVrh10 Enhances its Transduction of Spinal Cord and Therapeutic Efficacy in a Mutant SOD1 Model of ALS. *Neuroscience*, **2017**, 365, 192-205	3.9	14
13	A Single Injection of Recombinant Adeno-Associated Virus into the Lumbar Cistern Delivers Transgene Expression Throughout the Whole Spinal Cord. *Molecular Neurobiology*, **2016**, 53, 3235-3248	6.2	22
12	Adeno-associated Virus Serotype Vectors Efficiently Transduce Normal Prostate Tissue and Prostate Cancer Cells. *European Urology*, **2016**, 69, 179-81	10.2	7
11	CNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector. *Molecular Therapy - Nucleic Acids*, **2016**, 5, e338	10.7	48
10	Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. *Human Gene Therapy*, **2015**, 26, 432-42	4.8	226
9	AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E4418-27	11.5	34
8	The potential of adeno-associated viral vectors for gene delivery to muscle tissue. *Expert Opinion on Drug Delivery*, **2014**, 11, 345-364	8	65
7	State-of-the-art human gene therapy: part I. Gene delivery technologies. *Discovery Medicine*, **2014**, 18, 67-77	2.5	50
6	State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications. *Discovery Medicine*, **2014**, 18, 151-61	2.5	57
5	Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression. *PLoS ONE*, **2013**, 8, e60478	3.7	77
4	The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse. *Molecular Genetics and Metabolism*, **2012**, 105, 116-25	3.7	62
3	Suppression of premature termination codons as a therapeutic approach. *Critical Reviews in Biochemistry and Molecular Biology*, **2012**, 47, 444-63	8.7	72

2	Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation. *Molecular Genetics and Metabolism*, **2010**, 99, 62-71	3.7	33
1	Pharmacological suppression of nonsense mutations to treat genetic diseases. *FASEB Journal*, **2010**, 24, 187.2	0.9	